An ideal codrug design should be able to control drug release, offer selectivity during drug delivery, and break down into non-toxic fragments after biodegradation. Our design incorporates d-ribofuranose as the core, with carbamate and carbonate groups as linking joints, a phosphodiester moiety as an enzyme recognition site, and lenalidomide and paclitaxel as the constituent drugs. The codrug synthesis involves seven steps with a 33% overall yield. The target codrug increases its water solubility 685 times versus paclitaxel.

中文翻译：

---

β-d-核呋喃糖为核心，磷酸二酯部分为联合药物开发的酶识别位点


理想的联合药物设计应能够控制药物释放，在药物递送过程中提供选择性，并在生物降解后分解成无毒片段。我们的设计以 d-核糖为核心，以氨基甲酸酯和碳酸盐为连接关节，以磷酸二酯部分作为酶识别位点，来那度胺和紫杉醇为组成药物。联合药物合成涉及 7 个步骤，总产率为 33%。与紫杉醇相比，目标联合药物的水溶性增加了 685 倍。